MAP2K3 and type 2 diabetes mellitus: We identified protein effects on metabolic outcomes that were not observed in the ILLUMINATE trial: Copine-1 (CPNE1) and Mitogen-activated protein kinase 3 (MAPK3) levels decreased after torcetrapib treatment, which increased type 2 diabetes risk (β=0.026, P=3.81×10−6 and β=0.081, P=1.03×10−6, respectively).